Cargando…
Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients
Background: The Memorial Sloan–Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at the evaluation...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225945/ https://www.ncbi.nlm.nih.gov/pubmed/32230921 http://dx.doi.org/10.3390/cancers12040808 |
_version_ | 1783534171614871552 |
---|---|
author | Fiala, Ondrej Finek, Jindrich Poprach, Alexandr Melichar, Bohuslav Kopecký, Jindrich Zemanova, Milada Kopeckova, Katerina Mlcoch, Tomas Dolezal, Tomas Capkova, Lenka Buchler, Tomas |
author_facet | Fiala, Ondrej Finek, Jindrich Poprach, Alexandr Melichar, Bohuslav Kopecký, Jindrich Zemanova, Milada Kopeckova, Katerina Mlcoch, Tomas Dolezal, Tomas Capkova, Lenka Buchler, Tomas |
author_sort | Fiala, Ondrej |
collection | PubMed |
description | Background: The Memorial Sloan–Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at the evaluation of the impact of the MSKCC score on the outcomes in mRCC patients treated with first-line sunitinib, with a focus on the intermediate-risk group. Methods: Clinical data from 2390 mRCC patients were analysed retrospectively. Progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were analysed according to the MSKCC risk score. Results: ORR, median PFS, and OS for patients with one risk factor were 26.7%, 10.1, and 28.2 months versus 18.7%, 6.2, and 16.2 months, respectively, for those with two risk factors (ORR: p = 0.001, PFS: p < 0.001, OS: p < 0.001). ORR, median PFS, and OS were 33.0%, 17.0, and 44.7 months versus 24.1%, 9.0, and 24.1 months versus 13.4%, 4.5, and 9.5 months in the favourable-, intermediate-, and poor-risk groups, respectively (ORR: p < 0.001, PFS: p < 0.001, OS: p < 0.001). Conclusions: The results of the present retrospective study demonstrate the suitability of the MSKCC model in mRCC patients treated with first-line sunitinib and suggest different outcomes between patients with one or two risk factors. |
format | Online Article Text |
id | pubmed-7225945 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72259452020-05-18 Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients Fiala, Ondrej Finek, Jindrich Poprach, Alexandr Melichar, Bohuslav Kopecký, Jindrich Zemanova, Milada Kopeckova, Katerina Mlcoch, Tomas Dolezal, Tomas Capkova, Lenka Buchler, Tomas Cancers (Basel) Article Background: The Memorial Sloan–Kettering Cancer Center (MSKCC) prognostic model has been widely used for the prediction of the outcome of metastatic renal cell carcinoma (mRCC) patients treated with systemic therapies, however, data from large studies are limited. This study aimed at the evaluation of the impact of the MSKCC score on the outcomes in mRCC patients treated with first-line sunitinib, with a focus on the intermediate-risk group. Methods: Clinical data from 2390 mRCC patients were analysed retrospectively. Progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were analysed according to the MSKCC risk score. Results: ORR, median PFS, and OS for patients with one risk factor were 26.7%, 10.1, and 28.2 months versus 18.7%, 6.2, and 16.2 months, respectively, for those with two risk factors (ORR: p = 0.001, PFS: p < 0.001, OS: p < 0.001). ORR, median PFS, and OS were 33.0%, 17.0, and 44.7 months versus 24.1%, 9.0, and 24.1 months versus 13.4%, 4.5, and 9.5 months in the favourable-, intermediate-, and poor-risk groups, respectively (ORR: p < 0.001, PFS: p < 0.001, OS: p < 0.001). Conclusions: The results of the present retrospective study demonstrate the suitability of the MSKCC model in mRCC patients treated with first-line sunitinib and suggest different outcomes between patients with one or two risk factors. MDPI 2020-03-27 /pmc/articles/PMC7225945/ /pubmed/32230921 http://dx.doi.org/10.3390/cancers12040808 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fiala, Ondrej Finek, Jindrich Poprach, Alexandr Melichar, Bohuslav Kopecký, Jindrich Zemanova, Milada Kopeckova, Katerina Mlcoch, Tomas Dolezal, Tomas Capkova, Lenka Buchler, Tomas Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients |
title | Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients |
title_full | Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients |
title_fullStr | Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients |
title_full_unstemmed | Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients |
title_short | Outcomes According to MSKCC Risk Score with Focus on the Intermediate-Risk Group in Metastatic Renal Cell Carcinoma Patients Treated with First-Line Sunitinib: A Retrospective Analysis of 2390 Patients |
title_sort | outcomes according to mskcc risk score with focus on the intermediate-risk group in metastatic renal cell carcinoma patients treated with first-line sunitinib: a retrospective analysis of 2390 patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225945/ https://www.ncbi.nlm.nih.gov/pubmed/32230921 http://dx.doi.org/10.3390/cancers12040808 |
work_keys_str_mv | AT fialaondrej outcomesaccordingtomskccriskscorewithfocusontheintermediateriskgroupinmetastaticrenalcellcarcinomapatientstreatedwithfirstlinesunitinibaretrospectiveanalysisof2390patients AT finekjindrich outcomesaccordingtomskccriskscorewithfocusontheintermediateriskgroupinmetastaticrenalcellcarcinomapatientstreatedwithfirstlinesunitinibaretrospectiveanalysisof2390patients AT poprachalexandr outcomesaccordingtomskccriskscorewithfocusontheintermediateriskgroupinmetastaticrenalcellcarcinomapatientstreatedwithfirstlinesunitinibaretrospectiveanalysisof2390patients AT melicharbohuslav outcomesaccordingtomskccriskscorewithfocusontheintermediateriskgroupinmetastaticrenalcellcarcinomapatientstreatedwithfirstlinesunitinibaretrospectiveanalysisof2390patients AT kopeckyjindrich outcomesaccordingtomskccriskscorewithfocusontheintermediateriskgroupinmetastaticrenalcellcarcinomapatientstreatedwithfirstlinesunitinibaretrospectiveanalysisof2390patients AT zemanovamilada outcomesaccordingtomskccriskscorewithfocusontheintermediateriskgroupinmetastaticrenalcellcarcinomapatientstreatedwithfirstlinesunitinibaretrospectiveanalysisof2390patients AT kopeckovakaterina outcomesaccordingtomskccriskscorewithfocusontheintermediateriskgroupinmetastaticrenalcellcarcinomapatientstreatedwithfirstlinesunitinibaretrospectiveanalysisof2390patients AT mlcochtomas outcomesaccordingtomskccriskscorewithfocusontheintermediateriskgroupinmetastaticrenalcellcarcinomapatientstreatedwithfirstlinesunitinibaretrospectiveanalysisof2390patients AT dolezaltomas outcomesaccordingtomskccriskscorewithfocusontheintermediateriskgroupinmetastaticrenalcellcarcinomapatientstreatedwithfirstlinesunitinibaretrospectiveanalysisof2390patients AT capkovalenka outcomesaccordingtomskccriskscorewithfocusontheintermediateriskgroupinmetastaticrenalcellcarcinomapatientstreatedwithfirstlinesunitinibaretrospectiveanalysisof2390patients AT buchlertomas outcomesaccordingtomskccriskscorewithfocusontheintermediateriskgroupinmetastaticrenalcellcarcinomapatientstreatedwithfirstlinesunitinibaretrospectiveanalysisof2390patients |